Group 1 - The company reported a revenue of RMB 407 million for the year ending December 31, 2024, representing a year-on-year decrease of 12.21% [1] - The net loss for the year was RMB 91.207 million, a reduction of 75.16% compared to the previous year [1] - Research and development expenses amounted to RMB 134.7 million, down 74.49% year-on-year [1] - The revenue included sales of drugs (Avaratnib and Pralsetinib) totaling RMB 175 million, licensing fee income of RMB 204 million, and royalties from Shuglikizumab of RMB 28.81 million [1] - Licensing fee income increased by RMB 108 million or 113.1%, which significantly offset the decline in drug sales revenue [1] - The company has successfully launched four innovative drugs and received 16 NDA approvals covering nine indications since its establishment [1] - The current research pipeline includes 16 candidate drugs, featuring potential first-in-class or best-in-class ADCs, multi-specific antibodies, immunotherapies, and precision medicines [1] Group 2 - The company aims to enhance its internal development capabilities and continue investing in R&D to advance a strong and distinctive pipeline [2] - The goal is to maximize the global commercial potential of approved drugs through strategic partnerships and localized production [2]
基石药业-B(02616)发布年度业绩，收入4.07亿元 已成功上市4款创新药 并获得涵盖9个适应症的16项NDA批准